Alnylam Pharmaceuticals (ALNY) Finished Goods (2018 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Finished Goods for 9 consecutive years, with $44.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Finished Goods rose 30.48% year-over-year to $44.0 million; the trailing twelve-month figure through Jun 2026 stood at $44.0 million (up 30.48% YoY), and the FY2025 full-year result was $32.3 million, up 22.34% from the prior year.
• Finished Goods advanced to $44.0 million in Q2 2026 per ALNY's latest filing, from $39.0 million in the prior quarter.
• Across five years, Finished Goods topped out at $44.0 million in Q2 2026 and bottomed at $10.4 million in Q1 2022.
• Historically, Finished Goods has averaged $28.0 million across 5 years, with a median of $27.8 million in 2023.
• The widest YoY moves for Finished Goods: up 265.54% in 2022, down 24.18% in 2022.
• Over 5 years, Finished Goods stood at $25.6 million in 2022, then dropped by 1.89% to $25.1 million in 2023, then increased by 5.21% to $26.4 million in 2024, then increased by 22.34% to $32.3 million in 2025, then jumped by 36.18% to $44.0 million in 2026.
• According to Business Quant data, Finished Goods over the past three periods registered $44.0 million, $39.0 million, and $32.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.